Hengrui's HRS/BHB-1893 Improves Exercise Capacity in 52-Week Phase 2 Extension Study

• Hengrui Pharma and Braveheart Bio presented HRS/BHB-1893 Phase 2 extension results on November 6, 2026, at American Heart Association Scientific Sessions.
• The 52-week extension enrolled 42 adults with symptomatic obstructive hypertrophic cardiomyopathy.
• The investigational drug improved exercise capacity and patient-reported symptoms, with sustained reductions in obstruction to blood flow from the heart.
• No severe or serious adverse events occurred during treatment; two patients resumed treatment at lower doses following temporary declines in heart function.
• Most patients remained on the starting dose, supporting a simpler dosing approach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief on November 07, 2026, and is solely responsible for the information contained therein.